Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Nov 17;23(1):990.
doi: 10.1186/s12891-022-05964-9.

Higher reinfection rate after two-stage revision arthroplasty in patients with refractory diabetes mellitus: a retrospective analysis with a minimum ten-year follow up

Yu-Chih Lin  1   2   3 , Yi-Hsuan Lin  4 , Jian-Hong Chou  1 , Yu-Tai Lo  1 , Chih-Hsiang Chang  1   2   3 , Sheng-Hsun Lee  1   2   3 , Sheng-Hsuan Lin  5
Affiliations

Higher reinfection rate after two-stage revision arthroplasty in patients with refractory diabetes mellitus: a retrospective analysis with a minimum ten-year follow up

Yu-Chih Lin et al. BMC Musculoskelet Disord. .

Abstract

Background: Treatment protocols for two-stage revision arthroplasty with diabetes mellitus (DM) have not yet been established. The control of glycated hemoglobin (HbA1c) in two-stage revision arthroplasty is still debated. This study aimed to clarify the importance of preoperative HbA1c levels before each stage of revision arthroplasty and to analyze the risk factors for reinfection.

Methods: Five hundred eighty-eight patients suffered from first-time PJI and was treated in our institute from January 1994 to December 2010 were reviewed. The mean follow-up time was 13.8 (range, 10.2-24.8) years. Patients underwent two-stage revision arthroplasty with DM at presentation were included. The endpoint of the study was reinfection of the revision arthroplasty. Demographic, survivorship, and surgical variables were also analyzed.

Results: Eighty-eight patients were identified and grouped by HbA1c level before the first stage surgery: Groups 1 and 2 had HbA1c levels < 7% and ≥ 7%, respectively. Reinfection was identified in 4.55% (2/44) and 18.18% (8/44) of the patients in Groups 1 and 2, respectively. Survivorship analysis revealed correction of the HbA1c before the final stage of revision arthroplasty as an independent factor (p < 0.001). The identified risks for reinfection were HbA1c levels ≥ 7% before final-stage surgery, ≥ 3 stages of revision arthroplasty, and extended-spectrum beta-lactamase (ESBL)-Escherichia coli PJI.

Conclusion: The HbA1c level before the final stage of revision arthroplasty could affect staged revision arthroplasty outcomes. Therefore, the necessity of postponing the elective final-stage revision arthroplasty procedure for HbA1c control should be further investigated in the future.

Keywords: Diabetes mellitus; Glycated hemoglobin; Periprosthetic joint infection; Staged revision arthroplasty.

PubMed Disclaimer

Conflict of interest statement

The authors have no relevant financial or non-financial interests to disclose.

Figures

Fig. 1
Fig. 1
Survival curve of 2-stage revision arthroplasty free from reinfection by 1st HbA1c
Fig. 2
Fig. 2
Survival curve of 2-stage revision arthroplasty free from reinfection by final stage HbA1c
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Delanois RE, Mistry JB, Gwam CU, Mohamed NS, Choksi US, Mont MA. Current epidemiology of revision total knee arthroplasty in the United States. J Arthroplasty. 2017;32:2663–2668. doi: 10.1016/j.arth.2017.03.066. - DOI - PubMed
    1. Kamath AF, Ong KL, Lau E, Chan V, Vail TP, Rubash HE, et al. Quantifying the burden of revision total joint arthroplasty for periprosthetic infection. J Arthroplasty. 2015;30:1492–1497. doi: 10.1016/j.arth.2015.03.035. - DOI - PubMed
    1. Kurtz SM, Lau EC, Son MS, Chang ET, Zimmerli W, Parvizi J. Are we winning or losing the battle with periprosthetic joint infection: trends in periprosthetic joint infection and mortality risk for the medicare population. J Arthroplasty. 2018;33:3238–3245. doi: 10.1016/j.arth.2018.05.042. - DOI - PubMed
    1. Natsuhara KM, Shelton TJ, Meehan JP, Lum ZC. Mortality during total hip periprosthetic joint infection. J Arthroplasty. 2019;34:S337–S342. doi: 10.1016/j.arth.2018.12.024. - DOI - PubMed
    1. Xu C, Goswami K, Li WT, Tan TL, Yayac M, Wang SH, et al. Is Treatment of periprosthetic joint infection improving over time? J Arthroplasty. 2020;35:1696–702.e1. doi: 10.1016/j.arth.2020.01.080. - DOI - PubMed

Substances